Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC-Reference-Cited by-同舟云学术

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC

Published:2022-08 Issue:8 Volume:3 Page:100367
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Kim Dong-Wan,Gadgeel Shirish,Gettinger Scott N.,Riely Gregory J.,Oxnard Geoffrey R.,Mekhail Tarek,Schmid Peter,Dowlati Afshin,Heist Rebecca S.,Wozniak Antoinette J.,Singh Jatinder,Cha Edward,Spahn Jessica,Ou Sai-Hong Ignatius

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference14 articles.

1. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT);Barlesi;Lancet,2016

2. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update;Hanna;J Clin Oncol,2021

3. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study;Mok;Ann Oncol,2020

4. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017

5. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC;Herbst;N Engl J Med,2020

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature;Cancer Treatment Reviews;2024-09

2. Advancing non-small cell lung cancer treatment: the power of combination immunotherapies;Frontiers in Immunology;2024-07-02

3. Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial;JTO Clinical and Research Reports;2024-07

4. Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications;Expert Review of Clinical Immunology;2024-06-26

5. Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC;Expert Review of Anticancer Therapy;2024-04-21